Complement Therapeutics

Complement Therapeutics GmbH (CTx) is a German-headquartered biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases. The Company is a spinout from the University of Manchester and is based on the pioneering research of its founders into novel targets within the complement cascade. Our lead investigational product (CTx001) is being evaluated as a potential gene therapy for GA, a leading cause of blindness. Additional programs will evaluate potential therapeutic opportunities in other complement-mediated conditions. The Company has subsidiaries in the UK (Complement Therapeutics Ltd) and in the USA (Complement Therapeutics Inc) as well as research laboratories in Stevenage, UK. About Geographic Atrophy Geographic Atrophy (GA) is a leading cause of blindness in the elderly and represents the advanced stage of dry age-related macular degeneration. It is characterised by the progressive degeneration of photoreceptors, retinal pigment epithelium, and choriocapillaris, resulting in irreversible vision loss. GA affects over 5 million people globally and remains a significant unmet clinical need.